Molecular Partners to Present at Upcoming Healthcare Investor Conferences
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that CEO Patrick Amstutz will present at key healthcare investor events in January 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that CEO Patrick Amstutz will present at key healthcare investor events in January 2022. Key conferences include the H.C. Wainwright BioConnect 2022 on January 10, the JP Morgan 40th Annual Virtual Healthcare Conference on January 12, and the Baader Helvea Swiss Equities Conference on the same day. Additionally, Amstutz will participate in the Octavian Seminar 2022 on January 14. All presentations will be available for viewing on the Molecular Partners website.
Details
News Market Reaction – MOLN
The recorded move for MOLN in the trading session of this news was +0.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in several upcoming healthcare investor events in January, 2022.
Conference Presentation Details:
H.C. Wainwright BioConnect 2022 Conference
- Monday, January 10, 2022 at 12:00 pm ET (6:00 pm CET); on-demand on January 10-13, 2022
JP Morgan 40th Annual Virtual Healthcare Conference
- Wednesday, January 12, 2022 at 7:30 am ET (1:30 pm CET)
Baader Helvea Swiss Equities Conference
- Wednesday, January 12, 2022 at 10:30 am ET (4:30 pm CET)
Conference Participation Details:
The Octavian Seminar 2022
- Friday, January 14, 2022
All webcasted presentations will be made available on the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.